propranolol has been researched along with Response Evaluation Criteria in Solid Tumors in 1 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Response Evaluation Criteria in Solid Tumors: An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we report the results of dose escalation of a nonselective β-blocker (propranolol) with pembrolizumab in patients with metastatic melanoma." | 9.41 | Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. ( Allen, C; Attwood, K; Bucsek, MJ; Cedeno, CD; Drabick, JJ; Ernstoff, MS; Funchain, P; Gandhi, S; Ji, W; Knudsen, ES; Levis, M; Mohammadpour, H; Pandey, MR; Puzanov, I; Repasky, EA; Stack, S; Tario, JD; Wallace, PK; Witkiewicz, AK, 2021) |
| " Here, we report the results of dose escalation of a nonselective β-blocker (propranolol) with pembrolizumab in patients with metastatic melanoma." | 5.41 | Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. ( Allen, C; Attwood, K; Bucsek, MJ; Cedeno, CD; Drabick, JJ; Ernstoff, MS; Funchain, P; Gandhi, S; Ji, W; Knudsen, ES; Levis, M; Mohammadpour, H; Pandey, MR; Puzanov, I; Repasky, EA; Stack, S; Tario, JD; Wallace, PK; Witkiewicz, AK, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gandhi, S | 1 |
| Pandey, MR | 1 |
| Attwood, K | 1 |
| Ji, W | 1 |
| Witkiewicz, AK | 1 |
| Knudsen, ES | 1 |
| Allen, C | 1 |
| Tario, JD | 1 |
| Wallace, PK | 1 |
| Cedeno, CD | 1 |
| Levis, M | 1 |
| Stack, S | 1 |
| Funchain, P | 1 |
| Drabick, JJ | 1 |
| Bucsek, MJ | 1 |
| Puzanov, I | 1 |
| Mohammadpour, H | 1 |
| Repasky, EA | 1 |
| Ernstoff, MS | 1 |
1 trial available for propranolol and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2021 |